Docoh
Loading...

LMNX Luminex

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Company profile

Ticker
LMNX
Exchange
CEO
Nachum Shamir
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
742747608

LMNX stock data

(
)

Calendar

26 Feb 21
11 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Luminex earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Mar 21 Eric Shapiro Common Stock Grant Aquire A No No 32.76 12,057 394.99K 46,319
12 Mar 21 Eric Shapiro Stock Option Common Stock Grant Aquire A No No 23.09 51,084 1.18M 51,084
12 Mar 21 Nancy Fairchild Common Stock Grant Aquire A No No 32.76 12,515 409.99K 46,707
12 Mar 21 Nancy Fairchild Stock Option Common Stock Grant Aquire A No No 23.09 53,516 1.24M 53,516
12 Mar 21 Collins Charles J. Common Stock Grant Aquire A No No 32.76 14,652 480K 49,503
12 Mar 21 Collins Charles J. Stock Option Common Stock Grant Aquire A No No 23.09 64,868 1.5M 64,868
12 Mar 21 Todd C. Bennett Common Stock Grant Aquire A No No 32.76 16,788 549.97K 47,579
12 Mar 21 Todd C. Bennett Common Stock Payment of exercise Dispose F No No 32.76 2,875 94.19K 30,791
12 Mar 21 Todd C. Bennett Stock Option Common Stock Grant Aquire A No No 23.09 72,976 1.69M 72,976
12 Mar 21 Shamir Nachum Common Stock Grant Aquire A No No 32.76 61,050 2M 240,655

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

84.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 195 208 -6.3%
Opened positions 31 42 -26.2%
Closed positions 44 35 +25.7%
Increased positions 74 76 -2.6%
Reduced positions 65 62 +4.8%
13F shares
Current Prev Q Change
Total value 916.07M 1.11B -17.2%
Total shares 39.58M 42.13M -6.1%
Total puts 118.3K 43.6K +171.3%
Total calls 64K 56.7K +12.9%
Total put/call ratio 1.8 0.8 +140.4%
Largest owners
Shares Value Change
BLK Blackrock 8.16M $188.75M +5.9%
Vanguard 5.23M $120.89M +2.5%
RGM Capital 2.7M $62.5M +7.4%
Dimensional Fund Advisors 1.84M $42.6M -6.3%
STT State Street 1.57M $36.44M +4.9%
Copeland Capital Management 1.39M $32.03M +67.8%
GS Goldman Sachs 1.16M $26.93M -7.7%
Acadian Asset Management 1.15M $26.67M -20.9%
Millennium Management 963.5K $22.28M +2.1%
ATAC Neuberger Berman 958.16K $22.06M -0.9%
Largest transactions
Shares Bought/sold Change
Redmile 0 -914.11K EXIT
Select Equity 0 -908.29K EXIT
Renaissance Technologies 657.24K -695.8K -51.4%
Norges Bank 634.16K +634.16K NEW
Copeland Capital Management 1.39M +559.91K +67.8%
BLK Blackrock 8.16M +451.62K +5.9%
Investment Management Of Virginia 0 -447.61K EXIT
Ophir Asset Management Pty 434K +434K NEW
IVZ Invesco 308.68K -364.53K -54.1%
Grantham, Mayo, Van Otterloo & Co. 60.47K -333.93K -84.7%

Financial report summary

?
Management Discussion
  • •Consolidated revenue was $417.4 million for 2020, representing a 25% increase over revenue for 2019.
  • •Assay revenue of $211.9 million for 2020, representing an increase of 60% over 2019.
  • •Sample-to-answer assay revenue increased for 2020 by $33.2 million, or 49%, from 2019.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: affirmative, affix, affixing, age, Alex, annum, ascertained, avoid, Azar, bankruptcy, BARDA, BBP, benzyl, bifurcated, Britain, Butyl, calendar, carefully, CFTR, Chairman, Commissioner, Concurrent, concurrently, confirmed, congregation, consecutive, cooperation, cope, counterparty, coupon, cov, creditor, culminating, DBP, deal, deeply, default, DEHP, Delegated, deployed, devised, DIBP, Dibutyl, Diisobutyl, disadvantage, disciplinary, discrimination, doubling, drawn, EEE, embrace, empowerment, endeavor, endorsement, engendered, England, enroll, enrollment, ERG, EUA, exert, expeditiously, FAST, FDCA, FDPIC, feel, female, flagship, foregoing, foster, fostering, fractional, fun, GuavaSoft, heater, HHS, Iceland, IgG, inadequacy, incentivize, indenture, insolvency, intervention, Ireland, IRS, justified, justify, justifying, laid, Lehman, letter, Liechtenstein, living, lodge, magnitude, mental, mentoring, misleading, morale, motivate, nasopharyngeal, Northern, Norway, notice, nuclear, pandemic, paramount, parent, PBB, PBDE, phthalate, premium, promptly, proximity, question, racial, radiological, ramping, readability, regrettable, repay, repayment, resume, resurgence, revocation, revoke, revoked, reward, rewarding, rich, RSP, Scotland, Shield, shortly, size, social, sponsorship, stability, strike, strive, subsided, substance, Subtopic, supervisory, surrendered, suspected, swab, Switzerland, systematic, takeover, tandem, thing, thousand, threat, tool, trust, turnover, UK, UKCA, unavailable, uncollectible, unconditional, unfair, unforeseen, unlawful, unpaid, unsecured, unwind, unwinding, usability, variation, vastly, vivo, voluntarily, volunteer, waived, warfare, warrant, weighed, XYP
Removed: accessory, accomplishing, added, analyzing, answer, antibiotic, assemble, attached, attaching, bacteria, bacterial, bear, billion, bind, binding, biochemical, biomarker, blood, bonding, bought, broader, Bulletin, cancer, captured, carry, CDF, children, chronic, clinically, Clostridium, coated, coincide, cold, collaborating, compare, compatible, compound, constituted, contrast, contributor, convenience, customizing, daily, depict, diarrhea, differential, differentiation, displayed, distinctive, dosage, dosing, draft, ease, easy, elderly, emitting, empiric, encoded, enforced, enzymatic, extension, fingerprinting, flame, footprint, fungal, GBS, gold, histocompatibility, hydrogen, hypervirulent, IA, IDbox, identity, immunocompromised, immunologic, ineffective, inexpensive, influenza, inherited, injected, instrumentation, interested, intermediate, ionized, isoC, isoG, iteration, lab, makeup, marketable, MDx, meaningful, memo, Merck, minimizing, mistreated, mixed, mixture, myriad, NanoGrid, naturally, nucleotide, occurring, overuse, owed, pair, patenting, pattern, Physical, placement, Plastic, pneumonia, post, prescribe, prescribing, preserve, presidential, probe, protozoan, provisional, put, refreshed, regimen, reinvestment, remeasurement, request, researcher, retrospectively, revaluation, ribonucleic, room, RP, RTx, SAB, scarcity, scratch, season, shift, signature, simplifying, slim, spectrum, spot, station, stewardship, stool, stoppage, stored, stream, submitting, surface, SYNCTTM, synthetic, technique, template, therapy, tissue, today, topic, transcriptional, true, unnecessary, unpleasant, walkaway, worsening, yeast